DRES-17. BCL3 IS A 19q PASSENGER THAT PREDICTS RESPONSE TO ALKYLATING CHEMOTHERAPY IN GBM

INTRODUCTION: Despite the universal use of temozolomide (TMZ) in GBM, many patients experience minimal benefit. Moreover, TMZ can be deleterious due to its mutagenic nature. These findings underline the importance of predicting which patients will benefit from TMZ. DATA: Bcl-3 was identified as bein...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Wu, Longtao, Bernal, Giovanna, Cahill, Kirk, Pytel, Peter, Yamini, Bakhtiar
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2017
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691882/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.275
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi